Masayo Naito

Suggest Changes
Learn More
BACKGROUND Angiotensin-converting enzyme (ACE) inhibitors have been reported to reduce the response to erythropoietin (EPO) administration in chronic hemodialysis patients, but the mechanism for this(More)